Search

Displaying results 2381 - 2390 of 8410 in total
  1. Drug

    Primidone

    go.drugbank.com/drugs/DB00794
    ApprovedVet approved

    Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  2. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    [A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Nafamostat

    go.drugbank.com/drugs/DB12598
    Investigational

    The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. … Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties.

    Synonyms: p-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine
  4. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications. … When an epidermal layer was added, this approach became known as "skin equivalent", "composite culture" or "organotypical culture" [L2453].

  5. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    , the FDA updated its prescribing information to contraindicate the use of obeticholic acid in patients with PBC and advanced cirrhosis (e.g. those with portal hypertension or hepatic decompensation) due

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    Subasumstat

    go.drugbank.com/drugs/DB16406
    Investigational

    Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced

  7. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    These parasites can infect humans following ingestion of larvae in contaminated water or food. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  9. Drug

    Dobutamine

    go.drugbank.com/drugs/DB00841
    ApprovedInvestigational

    A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

    Synonyms: DL-dobutamine, (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
  10. Drug

    Prasugrel

    go.drugbank.com/drugs/DB06209
    ApprovedInvestigational

    Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates